Home・Elenco Azioni・Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals Inc

Chiusa

SettoreSettore sanitario

85.15 -1.95

Acquista Vendi

Panoramica

Variazione del prezzo dell'azione

24h

Corrente

Minimo

86.84

Massimo

90.31

Metriche Chiave
By Trading Economics
Entrata	-51M -184M
Vendite	1.5M 75M
P/E Media del settore	47.744 57.002
EPS	-1.36
Margine di Profitto	-244.188
Dipendenti	711
EBITDA	-47M -154M

Raccomandazioni
By TipRanks
Raccomandazioni	Fortemente da comprare
Previsioni per 12 mesi	+25.8% upside

Statistiche di mercato
By TradingEconomics
Capitalizzazione di Mercato	362M 12B
Apertura precedente	87.1
Chiusura precedente	85.15

Notizie sul Sentiment di mercato

By Acuity

20%

80%

32 / 340 Classifica in Healthcare

Arrowhead Pharmaceuticals Inc Grafico

Le prestazioni passate non sono un indicatore affidabile dei risultati futuri.

Notizie correlate

12 ago 2026, 21:01 UTC

Arrowhead Pharmaceuticals shares are higher in after-market hours, buoyed by positive market sentiment following comments on interest rates from Economic Advisor Phelan.

11 ago 2026, 19:36 UTC

Arrowhead Pharmaceuticals Inc is trading higher today, remaining above its 20-day moving average amid geopolitical tensions and anticipation of U.S. inflation reports.

6 ago 2026, 19:16 UTC

Arrowhead Pharmaceuticals Inc shares are lower during Thursday's session, despite earlier rebounding from a session high. No specific news was identified to explain the decline.

5 ago 2026, 21:36 UTC

Arrowhead Pharmaceuticals Inc is trading higher in after-market hours, reflecting strong performance and positioning above its 20-day moving average.

4 ago 2026, 23:02 UTC

Social Media

News

Arrowhead Pharmaceuticals shares fell in after-market trading following a net loss of $194.280 million and an EPS of -$1.36 in its fiscal Q3 results.

3 ago 2026, 19:36 UTC

Arrowhead Pharmaceuticals Inc is trading higher in Monday's session. Broader market positivity follows President Trump's military announcement, impacting crude oil prices.

31 lug 2026, 19:16 UTC

Correlated Moves

Arrowhead Pharmaceuticals shares are lower, reflecting broader pressures in the biotechnology sector amid rising inflation concerns linked to increased crude oil prices.

30 lug 2026, 23:06 UTC

Arrowhead Pharmaceuticals Inc shares declined in after-market trading, with no specific news identified to explain the movement amid broader market volatility.

29 lug 2026, 20:09 UTC

News

Social Media

RBC Capital raised Arrowhead Pharmaceuticals' price target to $100 from $87, contributing to positive sentiment and modest gains since Tuesday's close.

28 lug 2026, 23:31 UTC

Arrowhead Pharmaceuticals shares are lower in after-market trading, continuing a decline since Tuesday's close amid broader market weakness and significant declines in other indices.

27 lug 2026, 19:02 UTC

News

Social Media

Event

Arrowhead Pharmaceuticals completed enrollment in its Phase 3 YOSEMITE trial for zodasiran, with H.C. Wainwright and Morgan Stanley raising price targets to $115 and $120, respectively.

24 lug 2026, 19:12 UTC

Social Media

Morgan Stanley raised its price target for Arrowhead Pharmaceuticals to $120, but shares are trading lower amid increased market volume during Friday's session.

23 lug 2026, 10:16 UTC

News

Event

Arrowhead Pharmaceuticals shares rise in pre-market trading, building on Wednesday's gains after positive drug trial results and a price target increase to $115 from $90.

22 lug 2026, 22:06 UTC

Event

Arrowhead Pharmaceuticals reported positive topline results from its Phase 3 SHASTA-3 and SHASTA-4 studies, boosting shares higher in after-market trading.

21 lug 2026, 20:12 UTC

Arrowhead Pharmaceuticals Inc. shares declined in after-market trading, remaining below the 20-day moving average and near the lower end of the one-month range.

20 lug 2026, 20:21 UTC

Arrowhead Pharmaceuticals Inc shares are lower in after-market hours, declining from a high to a low amid unusual trading activity and no specific news identified.

Confronto tra pari

Modifica del prezzo

Arrowhead Pharmaceuticals Inc Previsione

Obiettivo di Prezzo

By TipRanks

25.8% in crescita

Previsioni per 12 mesi

Media 109.76 USD 25.8%

Alto 126 USD

Basso 89.59 USD

Basato su 10 analisti di Wall Street che offrono Obiettivi di Prezzo a 12 mesi per Arrowhead Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Consenso sulla valutazione

By TipRanks

Fortemente da comprare

10 ratings

Acquista

Mantieni

Vendi

Basato sugli analisti di 10 che hanno fornito valutazioni azionarie a Arrowhead Pharmaceuticals Inc - Dist negli ultimi 3 mesi.

Sentiment

By Acuity

32 / 340 Classifica in Settore sanitario

Notizie finanziarie

Spese di vendita e di amministrazione

Spese operative

Utile prima delle imposte

Vendite

Costo delle vendite

Utile lordo sulle vendite

Interessi passivi sul debito

EBITDA

Utile operativo

Chi Siamo Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.